U.S. Markets open in 3 hrs 40 mins
  • Crude Oil

    71.35
    +1.06 (+1.51%)
     
  • Gold

    1,766.50
    +2.70 (+0.15%)
     
  • Silver

    22.22
    +0.05 (+0.23%)
     
  • EUR/USD

    1.1738
    +0.0011 (+0.0939%)
     
  • 10-Yr Bond

    1.3090
    0.0000 (0.00%)
     
  • Vix

    23.00
    +2.19 (+10.52%)
     
  • GBP/USD

    1.3690
    +0.0031 (+0.2259%)
     
  • USD/JPY

    109.5650
    +0.1450 (+0.1325%)
     
  • BTC-USD

    44,590.88
    -3,435.44 (-7.15%)
     
  • CMC Crypto 200

    1,085.90
    -48.48 (-4.27%)
     
  • FTSE 100

    6,975.04
    +71.13 (+1.03%)
     
  • Nikkei 225

    29,839.71
    -660.34 (-2.17%)
     

AcelRx Pharmaceuticals, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Investors with losses are encouraged to contact the firm before August 9, 2021; click here to submit trade information

LOS ANGELES, July 30, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) investors that acquired shares between March 17, 2020 to February 12, 2021. Investors have until August 9, 2021 to seek an active role in this litigation.

Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case.

It is alleged in this complaint that throughout the Class Period, AcelRx made materially misleading and false statements and/or failed to disclose that: (1) AcelRx’s disclosure controls and procedures with respect to its marketing of DSUVIA were deficient; (2) AcelRx had been making misleading or false claims and representations about the risks and efficacy of DSUVIA in certain advertisements and displays, as a result; (3) the foregoing conduct subjected AcelRx to increased regulatory enforcement and scrutiny; and (4) AcelRx’s public statements were materially false and misleading at all relevant times, as a result.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 9, 2021.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com

Attorney Advertising